CytomX Therapeutics’ (CTMX) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research report released on Monday morning,Benzinga reports. Guggenheim currently has a $10.00 target price on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright upped their price objective on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Cantor Fitzgerald raised their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Barclays increased their price target on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Finally, Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.00.

CytomX Therapeutics Stock Performance

CTMX opened at $5.03 on Monday. The firm has a market cap of $852.23 million, a P/E ratio of 12.58 and a beta of 2.44. CytomX Therapeutics has a 52-week low of $0.40 and a 52-week high of $6.35. The business’s fifty day moving average is $5.14 and its 200-day moving average is $3.96.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP bought a new stake in shares of CytomX Therapeutics in the 4th quarter valued at about $208,000. Empowered Funds LLC bought a new position in shares of CytomX Therapeutics during the fourth quarter worth about $133,000. XTX Topco Ltd lifted its stake in shares of CytomX Therapeutics by 63.9% in the fourth quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 18,705 shares during the period. Virtus Investment Advisers LLC bought a new stake in CytomX Therapeutics in the fourth quarter valued at approximately $270,000. Finally, Twinbeech Capital LP bought a new stake in CytomX Therapeutics in the fourth quarter valued at approximately $75,000. 67.77% of the stock is owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.